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thrombosis of the lower limb
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Simon Panzer, MD,c and Renate Koppensteiner, MD,a Vienna, Austria
Background: Soluble p-selectin (sP-selectin), D-dimer, and C-reactive protein (CRP) are elevated in deep vein thrombosis
(DVT), and may play a role as risk predictors of recurrent venous thromboembolism. However, these parameters have
only been assessed at manifestation or at single time points after DVT so far. We therefore investigated the course of
sP-selectin, D-dimer, and high-sensitivity (hs)-CRP after acute unprovoked DVT of the lower limb.
Methods: In this prospective, longitudinal study, sP-selectin, D-dimer, and hs-CRP were determined by enzyme-linked
immunosorbent assay, quantitative latex assay, and particle enhanced immunonephelometry, respectively, in 44 patients
with sonographically confirmed acute DVT at the time of diagnosis, and 1, 3, 6, and 12 months later. sP-selectin and
hs-CRP were also measured in 88 age- and gender-matched healthy controls. Further, color duplex sonography was
performed in all patients at each time point.
Results: At DVT diagnosis, sP-selectin and hs-CRP were significantly higher in patients compared with healthy controls.
From baseline to 1 month, both parameters decreased significantly. In patients with oral anticoagulation (OAC) for 6
months (n  35), levels of sP-selectin increased significantly after cessation of anticoagulant therapy (P  .002), while
sP-selectin was similar to healthy controls in patients with ongoing OAC (n  9) at 12 months (P  .49). In contrast,
hs-CRP in both subgroups remained constantly low at levels seen in healthy controls. The course of D-dimer was similar
to sP-selectin. Color duplex sonography showed no ongoing thrombus formation in any patient. Thirty-four (77.3%), 29
(65.9%), 26 (59.1%), and 25 (56.8%) patients had residual thrombosis 1, 3, 6, and 12 months after the acute event,
respectively. D-dimer was significantly higher in patients with residual thrombosis compared with patients without
residual thrombosis 1 month after DVT (0.58 g/mL [range, 0.2-9.67 g/mL] vs 0.25 g/mL [range, 0.2-0.62
g/mL]; P  .02). At all other time points, the levels of D-dimer and sP-selectin did not differ significantly between
patients without and with residual thrombosis (all P > .05).
Conclusions:Concentrations of sP-selectin andD-dimer after acute DVT seem to be strongly influenced by treatment with
vitamin K antagonists. After withdrawal of oral anticoagulation, they rise again and could therefore reflect a prothrom-
botic state, which is susceptible to pharmacologic therapy. (J Vasc Surg 2011;54:48S-55S.)
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pP-selectin (CD62) is localized in the alpha granules
of platelets and the Weibel-Palade bodies of endothelial
cells, and belongs to the selectin family of cell adhesion
molecules.1 It mediates binding to specific carbohydrate-
containing ligands, like P-selectin glycoprotein ligand-1,
which is present on the majority of leukocytes and in
smaller amounts on platelets.2,3 Thereby, it supports initial
tethering of leukocytes to activated endothelial cells and
platelets, and mediates leukocyte rolling on the endothelial
cell surface.4 The detection of platelet expression of P-
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48Selectin became one of the most important parameters to
emonstrate platelet activation.
Soluble P-selectin (sP-selectin) is a circulating form of
-selectin, which results from shedding of the extracellular
omain and maintains the requirements for ligand bind-
ng.5,6 If plasma sP-selectin derives mainly from the
eibel-Palade bodies of endothelial cells or from platelets
s not known yet. However, there is growing evidence that
latelet activation results in higher levels of sP-selectin.7-10
urther, the degranulation of the Weibel-Palade bodies by
esmopressin did not increase sP-selectin, suggesting that
ndothelial activation alone does not significantly add to
P-selectin.11 Therefore, it can be assumed that sP-selectin
s mainly platelet-derived and reflects platelet activation.8
Plasma levels of sP-selectin are elevated in acute deep
ein thrombosis (DVT).12-14 Further, high levels of sP-
electin were recently associated with an increased risk for
ecurrence of DVT,15,16 and in cancer patients, high
lasma levels of sP-selectin were predictive of venous
hromboembolism (VTE).17 However, it remains unclear
hether and how long sP-selectin stays elevated after acute
VT. This may be of relevance to determine the best time
oint for sP-selectin measurements to estimate the risk for
ecurrence of DVT.
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Volume 54, Number 19S Gremmel et al 49SD-dimer is a degradation product of cross-linked fibrin.
Elevated levels of D-dimer indicate coagulation activation
and fibrinolysis, and have been associated with an increased
risk of first and recurrent VTE.18,19 Recently, D-dimer was
incorporated in a scoring system to assess the risk of recur-
rence in patients with a first unprovoked VTE.20
C-reactive protein (CRP) is an acute phase protein,
which is elevated in VTE. Currently there are conflicting
data on the potential causal relationship between increased
plasma concentrations of CRP and the development of
VTE.21 While several studies reported an increased risk of
VTE in patients with elevated levels of CRP,22,23 others
found no such association.24,25 Most studies investigating
the relationship between CRP and VTE assessed CRP
before or at only one time point after DVT.14,22-26 Conse-
quently, data on the course of CRP after acute DVT are
missing so far. These data would contribute to the under-
standing of the role of CRP in VTE, and add further
evidence to a potential causal relationship between both.
We therefore sought to investigate the course of sP-
selectin, D-dimer, and high-sensitivity (hs)-CRP after acute
DVT of the lower limb.
METHODS
Patients. In this prospective, longitudinal study, 46
consecutive patients with acute unilateral symptomatic
DVT of the lower limb were included and followed for 1
year. All patients were diagnosed at the outpatient depart-
ment of the Division of Angiology of the Medical Univer-
sity of Vienna, and diagnosis of DVT was confirmed in all
patients by color duplex sonography. Two patients were
excluded from the study because of the detection of malig-
nant tumors during the diagnostic workup of DVT. The
remaining 44 patients suffered acute unprovoked DVT.
UnprovokedDVTwas defined as thrombosis without a
triggering event (ie, surgery, trauma causing immobiliza-
tion, pregnancy, delivery, or malignancy). Events that oc-
curred while the patient was taking oral contraceptives were
also considered as unprovoked, because such treatment had
been continued for a long time and was probably not the
trigger for DVT.
Exclusion criteria were active malignancy, life expectancy
2 years, ongoing anticoagulant treatment at study entry, and
age 18 years. All patients were initially treated with low
molecular weight heparin and switched to vitamin K antago-
nists with a therapeutic target international normalized ratio
of 2 to 3 after contraindications for oral anticoagulation had
been excluded. Thirty-five patients (79.5%) received oral an-
ticoagulation (OAC) for 6months. Nine patients (20.5%) still
received OAC at 12-month follow-up because of prior VTE
(n  4; 44.4%), concomitant pulmonary embolism (n  3;
33.3%), or extensive DVT (n  2; 22.2%). All four patients
with prior VTE had experienced prior DVT 2 years before
the recurrent DVT, and had been treated with OAC for 6
months back then.
For each patient, we included two healthy controls.
Thereby, 88 healthy individuals without antithrombotic
therapy and with no medical history of VTE or arterial shrombosis served as controls for levels of sP-selectin and
s-CRP. The control group was matched to the patient
roup by gender and age in a whole-group- and not pair-
ise-manner. Healthy controls were from the same geo-
raphic region and ethnic background as the patients.
The study protocol was approved by the Ethics Com-
ittee of the Medical University of Vienna in accordance
ith the Declaration of Helsinki, and written informed
onsent was obtained from all study participants.
Blood sampling. Blood was drawn by clean venipunc-
ure from an antecubital vein using a 21-gauge butterfly
eedle (0.8  19 mm; Greiner Bio-One, Kremsmünster,
ustria) at diagnosis of acute DVT, and 1, 3, 6, and 12
onths later.27 To avoid procedural deviations, all blood
amples were taken by the same physician applying a light
ourniquet, which was immediately released, and the
amples were mixed adequately by gently inverting the
ubes. The first 3 mL of blood were discarded to reduce
rocedurally-induced platelet activation. Blood was drawn
nto a 3.8% sodium citrate Vacuette tube (9 parts of whole
lood, 1 part of sodium citrate 0.129 M/L) for sP-selectin
nd D-dimer measurements, and into a serum Vacuette
ube (both Greiner Bio-One) for the determination of
s-CRP. Blood samples were obtained from all patients at
ach follow-up.
Measurement of sP-selectin, D-dimer, hs-CRP, and
brinogen. Measurements of sP-selectin were carried out
n duplicates using 100-L plasma diluted 20-fold into
ample diluent included in the enzyme-linked immunosor-
ent assay (ELISA) reagent set (Human sP-selectin/
D62P ELISA reagent set; R&D Systems, Minneapolis,
inn). The absorbance at 450 nm was measured on a mic-
oplate reader (MR7000; Dynex Technologies/Dynatech
aboratories, Chantilly, Va). The sP-selectin concentration
as determined from a calibration curve generated with Rev-
lation software (version G 3.2) from Dynex Technologies.
D-dimer levels were measured by a quantitative latex
ssay (STA-LIAtest D–DI; Diagnostica Stago, Asnières,
rance) on a STA-R analyzer (Diagnostica Stago).
hs-CRP was measured with a fully automated particle
nhanced immunonephelometry (N high sensitivity CRP,
ade Behring, Marburg, Germany) on a Behring nephe-
ometer II (BN Systems, Orchard Park, NY).
Fibrinogen was determined according to Clauss (STA
ibrinogen, Diagnostica Stago; normal range 180-390 mg/
L).
Color duplex sonography. Color duplex sonography
as performed at baseline, and 1, 3, 6, and 12 months after
cute DVT at the Division of Angiology of the Medical
niversity of Vienna. To avoid investigator-related variations
f the results, color duplex sonographywas performed in each
atient by the same investigator at all time points.
Statistical analysis. Statistical analysis was performed
sing the Statistical Package for Social Sciences (SPSS
ersion 15.0; SPSS, Chicago, Ill) on a per-person basis.
edian and range of continuous variables are shown. We
erformed Mann-Whitney U tests to detect differences of
P-selectin and hs-CRP between patients and healthy con-
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D-dimer, and hs-CRP between the various time points.
The 2 test was used to detect differences in categorical
variables. Spearman rank correlation was used to test for
correlations. Two-sided P values .05 were considered
statistically significant.
RESULTS
Table I summarizes clinical and laboratory characteris-
tics of patients and healthy controls. Patients had signifi-
cantly higher leukocyte counts than healthy controls at all
time points. The leukocyte count was not significantly
associated with levels of sP-selectin (all r  .2, all P  .2).
Nine patients (20.4%) were taking oral contraceptives at the
time of DVT diagnosis. Twenty-three patients (52.3%) had
iliofemoral DVT, nine patients (20.4%) had femoropopli-
teal DVT, and 12 patients (27.3%) had distal DVT. sP-
selectin, D-dimer, hs-CRP, platelet count, and leukocyte
count of patients with OAC for 6 and 12 months at the
various time points are given in Table II.
At diagnosis of acute DVT, sP-selectin was significantly
higher in patients than in healthy controls (41.4 g/L
[range, 20.6-79.1 g/L] vs 33.1 g/L [range, 11.7-63.9
g/L]; P  .001; Fig 1, A). From baseline to 1 month,
sP-selectin decreased significantly in the patient population
Table I. Clinical and laboratory characteristics of patients an
Patients (n 44)
Age 51 (21-81)
Female gender, n (%) 22 (50)
Body mass index, kg/m2 28.6 (17.9-40.1)
Smoking, n (%) 12 (27.3)
Platelet count, giga/liter 219 (128-463)
Leukocyte count, giga/
liter
7.4 (3.3-12.9)
Erythrocyte count, tera/
liter
4.6 (3-6.4)
Continuous data are shown as median (range); dichotomous data are show
Table II, A. sP-selectin (g/L), D-dimer (g/mL), hs-C
(G/L) at diagnosis of acute deep vein thrombosis (DVT),
anticoagulant therapy for 6 months
Baseline 1 month 3
sP-selectin
40.5 (20.6-79.1) 33.4 (19.4-57.6)a 27.7 (
D-dimer
1.86 (0.33-24.06) 0.38 (0.2-9.67)a 0.29 (
hs-CRP
0.86 (0.03-10.6) 0.32 (0.03-4.06)a 0.17 (
Platelet count
223 (128-463) 242 (101-568) 231 (
Leukocyte count
7.3 (3.3-11.6) 6 (3.8-11.1)a 5.8 (
hs-CRP, High-sensitivity C-reactive protein; sP-selectin, soluble P-selectin.
Continuous data are given as median (range).
aP  .05 compared with previous visit.(P .001). One month after acute DVT, sP-selectin levels tn patients were similar to healthy controls (32.4 g/L
range, 17.5-57.6 g/L] vs 33.1 g/L [range, 11.7-63.9
g/L]; P  .33). From 1 to 3 months, sP-selectin levels
howed a significant further decrease (P  .02). At 3
onths, sP-selectin levels in patients were significantly
ower than in healthy controls (28 [range, 16.7-84.4] vs
3.1 g/L [range, 11.7-63.9 g/L]; P  .007). The
-month sP-selectin levels were similar to the 3-month
alues (P .41), and still lower than in the healthy control
opulation. In patients with OAC for 6 months, sP-selectin
ncreased significantly after cessation of anticoagulant ther-
py (Table II, A; P  .002) and was significantly higher
han in healthy controls at 12 months (P  .001). In
ontrast, sP-selectin remained similar to healthy controls in
atients with ongoing OAC at 12 months (Table II, B;
 .49).
Patients with distal DVT showed a strong trend toward
ower sP-selectin levels than patients with femoropopliteal
VT at the time of diagnosis (35.7 g/L [range, 27.3-
4.8 g/L] vs 43 g/L [range, 20.6-79.1 g/L]; P 
08). Thereby, sP-selectin values of patients with distal
VT were similar to healthy controls at diagnosis and 1
onth after DVT. Three and 6 months after DVT, sP-
electin concentrations in this subgroup were significantly
ower than in healthy controls (both P  .05). After cessa-
lthy controls at diagnosis of deep vein thrombosis (DVT)
Healthy controls (n 88) P value
53 (25-83) .5
44 (50) 1
26.4 (19.5-46.4) .2
17 (19.3) .3
229 (129-440) .8
5.4 (2.6-11.1) .001
4.6 (3.6-5.5) .5
mber (%).
mg/dL), platelet count (G/L), and leukocyte count
, 3, 6, and 12 months later in patients (n  35) with
hs 6 months 12 months
84.4) 29.6 (14.4-104.2) 51.8 (14.4-111.8)a
.05)a 0.27 (0.2-0.95) 0.42 (0.2-3.3)a
2.4) 0.19 (0.03-5.05) 0.17 (0.03-2.23)
513) 227 (88-456) 220 (130-476)
2) 6.2 (3.8-9.5) 6.2 (4-13.4)d heaRP (
and 1
mont
16.7-
0.2-1
0.03-
108-
3.7-1ion of anticoagulation, their sP-selectin levels increased
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(31.1 g/L [range, 14.4-94.4 g/L] vs 33.1 g/L
[range, 11.7-63.9 g/L]). The course of sP-selectin in
each patient at all time points is given in Fig 2, A.
The course of D-dimer was similar to sP-selectin (Fig 2,
B). D-dimer decreased significantly from baseline to 1
month, and from 1 month to 3 months after DVT (both
P  .001). In patients treated with OAC for 6 months,
D-dimer increased significantly after withdrawal of antico-
agulant therapy (Table II, A), while it remained low in
patients with ongoing OAC (Table II, B).
At the time of diagnosis, hs-CRP was significantly
higher in patients than in healthy controls (1.16 mg/dL
[range, 0.03-10.6 mg/dL] vs 0.15 mg/dL [range, 0.02-
2.63 mg/dL]; P  .001; Fig 1, B). From baseline to 1
month, hs-CRP decreased significantly in the patient pop-
ulation (P  .001). At 1 month, hs-CRP was still signifi-
cantly higher in patients than in healthy controls (0.25
mg/dL [range, 0.03-4.06 mg/dL] vs 0.15 mg/dL [range,
0.02-2.63mg/dL]; P .004). From 1month to 3months
hs-CRP showed a nonsignificant further decrease. Thereaf-
ter, hs-CRP levels in patients were constantly low and
similar to healthy controls (all P  .05). Moreover, the
course of hs-CRP did not differ significantly between pa-
tients with OAC for 6 and 12 months, respectively (Table
II). The course of hs-CRP was similar between patients
with distal and proximal DVT (Fig 2, C).
At DVT diagnosis, fibrinogen was significantly higher
in patients than in healthy controls (391 mg/dL [range,
281-658 mg/dL] vs 346 mg/dL [range, 207-529 mg/
dL]; P  .001). Fibrinogen remained elevated in the pa-
tient population at 1, 3, and 6 months. From 6 to 12
months, fibrinogen levels in patients decreased and were
not significantly different from those in healthy controls at
12 months (373 mg/dL [range, 225-669 mg/dL] vs 346
mg/dL [range, 207-529 mg/dL]; P  .23). Fibrinogen
was not significantly associated with sP-selectin levels at all
time points (all r  .28, all P  .05).
Color duplex sonography showed no ongoing throm-
Table II, B. sP-selectin (g/L), D-dimer (g/mL), hs-CR
at diagnosis of acute deep vein thrombosis (DVT), and 1,
anticoagulant therapy at 12 months
Baseline 1 month
sP-selectin
45 (32.8-52.1) 31.2 (17.5-45.1)a 28.
D-dimer
2.45 (0.83-17.28) 0.43 (0.2-0.74)a 0.2
hs-CRP
1.65 (0.07-3) 0.15 (0.05-0.81)a 0.1
Platelet count
216 (140-391) 202 (165-390) 19
Leukocyte count
7.8 (4.9-12.9) 7.1 (4.6-9.8) 6.
hs-CRP, High-sensitivity C-reactive protein; sP-selectin, soluble P-selectin.
Continuous data are given as median (range).
aP  .05 compared with previous visit.bus formation or extension of DVT in any patient. Thirty- iour (77.3%), 29 (65.9%), 26 (59.1%), and 25 (56.8%)
atients had residual thrombosis 1, 3, 6, and 12 months
fter the acute event, respectively. D-dimer was signifi-
antly higher in patients with residual thrombosis com-
ared with patients without residual thrombosis 1 month
fter DVT (0.58 g/mL [range, 0.2-9.67 g/mL] vs 0.25
g/mL [range, 0.2-0.62 g/mL], P  .02). At all other
ime points, the levels of D-dimer and sP-selectin did not
iffer significantly between patients without and with resid-
al thrombosis (all P  .05).
One patient (2.3%) with OAC for 6 months suffered a
ulmonary embolism a few weeks after the 12-month fol-
ow-up. The sP-selectin concentration of this patient prior
o the adverse event was 41.7 g/L, the D-dimer concen-
ration was 2.45 g/mL, and hs-CRP was 0.31 mg/dL.
he other patients remained free from recurrent VTE
uring clinical follow-up.
ISCUSSION
To the best of our knowledge, this is the first study
nvestigating the course of sP-selectin, D-dimer, and hs-CRP
ver a period of 12months after acuteDVTof the lower limb.
ll parameters were elevated in the acute phase and decreased
ignificantly within the first month after DVT. After termina-
ion of oral anticoagulation, sP-selectin and D-dimer in-
reased significantly from 6 to 12months while hs-CRP levels
emained low and similar to healthy controls.
By showing that sP-selectin was increased in acuteDVT
nd 6 months after cessation of anticoagulant therapy, our
ata are in line with previous observations.12,13,16,28 More-
ver, our data show that during therapy with vitamin K
ntagonists, sP-selectin concentrations decreased and reached
ower levels than in healthy controls 3 and 6 months after
VT. These findings suggest that increased sP-selectin
evels after DVT may be the result of platelet activation by
hrombin. Thrombin-dependent platelet activation may
ead to increased expression of P-selectin on the platelet
urface and by shedding of platelet P-selectin, increased
evels of sP-selectin. As long as thrombin generation is
g/dL), platelet count (G/L), and leukocyte count (G/L)
and 12 months later in patients (n  9) with ongoing
nths 6 months 12 months
.4-33.8) 30.1 (20.8-44.8) 35 (19.3-137.8)
-0.48)a 0.24 (0.2-0.78) 0.28 (0.2-1.35)
3-0.59) 0.09 (0.05-0.87) 0.12 (0.1-0.45)
3-363) 196 (149-345) 201 (144-330)
2) 7.2 (5.2-9.3) 7.5 (5.2-10.4)P (m
3, 6,
3 mo
5 (18
7 (0.2
7 (0.0
9 (16
5 (6-1nhibited by vitamin K antagonists, sP-selectin stays low,
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December Supplement 201152S Gremmel et albut after withdrawal of anticoagulant treatment, levels of
sP-selectin rise again and reach similar values like in acute
DVT within a few months. The increased levels of sP-
selectin after discontinuation of anticoagulant therapy may
therefore represent an ongoing hypercoagulable state. This
is further supported by the observation that the course of
D-dimer was similar to sP-selectin in our patient popula-
tion. Indeed, Kyrle et al recently showed that patients with
the highest concentrations of sP-selectin after withdrawal
of anticoagulation are at an increased risk of recurrent VTE
compared with patients with sP-selectin values in the first
Fig 1. A, sP-selectin in patients and healthy controls at diagnosis
of acute deep vein thrombosis. The boxes represent the IQR, the
ends of the whiskers represent the lowest datum still within 1.5 IQR
of the lower quartile, and the highest datum still within 1.5 IQR of
the upper quartile. B, hs-CRP in patients and healthy controls at
diagnosis of acute deep vein thrombosis. The boxes represent the
IQR, the ends of the whiskers represent the lowest datum still within
1.5 IQR of the lower quartile, and the highest datum still within
1.5 IQR of the upper quartile. hs-CRP,High-sensitivity C-reactive
protein; IQR, interquartile range; sP-selectin, soluble P-selectin.three quartiles.15 Further, Ay et al reported increased levels af sP-selectin in patients with recurrent VTE,16 and various
tudies found increased levels of D-dimer to predict first
nd recurrent VTE.18-20
Nevertheless, it remains unclear if this hypercoagu-
able state precedes and promotes the development of
VT, or rather is a consequence of VTE. Interestingly,
xperimental studies reported sP-selectin to induce the
eneration of procoagulant microparticles and to trigger
ncreased tissue factor expression on monocytes.29,30
urther, sP-selectin was shown to induce phosphatidyl-
erine exposure and to increase surface-dependent
hrombin generation on monocytes.31 Myers et al dem-
nstrated in a mouse model that high levels of sP-selectin
re associated with increased thrombosis,32,33 and sev-
ral studies showed that P-selectin inhibition was associ-
ted with a strong antithrombotic effect.29,34-37 These
revious findings support the hypothesis that sP-selectin
romotes thrombus formation and plays an active role in
he development of VTE. However, in the subgroup of
atients with distal DVT, sP-selectin levels were similar
o healthy controls and significantly lower than in pa-
ients with iliofemoral and femoropopliteal DVT, sug-
esting that concentrations of sP-selectin are dependent
n the extent of thrombus formation. Therefore, in-
reased sP-selectin levels after DVT may at least in part
lso be a consequence of DVT. Since the number of
atients with distal DVT was rather small in our patient
opulation, further studies are warranted to investigate
he interrelation between distal DVT and levels of sP-
electin.
Our data, however, suggest that sP-selectin and D-dimer
re influenced by therapy with vitamin K antagonists. Conse-
uently,measurements of both parameters to estimate the risk
or recurrence of DVT should be performed in an appropriate
nterval after withdrawal of anticoagulation. Previous studies
lso reported a significant reduction of sP-selectin by statin
herapy.38,39 Therefore, sP-selectin appears to be a marker or
ven a trigger of a prothrombotic state, which can be influ-
nced by pharmacologic intervention.
In contrast to sP-selectin and D-dimer, hs-CRP did not
ise again after cessation of anticoagulation, suggesting that its
ourse after DVT is independent of treatment with vitamin K
ntagonists. The elevated levels of hs-CRP in acute DVTmay
e caused by the acute phase reaction. This hypothesis is
upported by the observation that fibrinogen, which is also
onsidered an acute phase protein,was similarly elevated in the
rst months after DVT, but decreased from 6 to 12 months.
owever, sincewe did notmeasure hs-CRPprior toDVT,we
annot exclude that elevated hs-CRP levels at least in part
ontributed to the development of DVT.
Only one patient in the study population suffered re-
urrent VTE. Both sP-selectin and D-dimer were elevated
n this patient prior to recurrent VTE. However, our study
as not designed to reveal differences regarding the clinical
utcome of patients with increased levels of sP-selectin or
-dimer after cessation of OAC. Previous studies reported
n increased risk for recurrent VTE in patients with elevated
JOURNAL OF VASCULAR SURGERY
Volume 54, Number 19S Gremmel et al 53SFig 2. A, Soluble p-selectin (sP-selectin) level of each patient at baseline (0), 1 month (1), 3 months (3), 6 months (6),
and 12 months (12) in patients with oral anticoagulation (OAC) for 12 months, patients with OAC for 6 months and
distal deep vein thrombosis (DVT), and patients with OAC for 6 months and proximal DVT. B,D-dimer level of each
patient at baseline (0), 1 month (1), 3 months (3), 6 months (6), and 12 months (12) in patients with OAC for 12
months, patients with OAC for 6 months and distal DVT, and patients with OAC for 6 months and proximal DVT. C,
High-sensitivity C-reactive protein (hs-CRP) level of each patient at baseline (0), 1 month (1), 3 months (3), 6 months
(6), and 12 months (12) in patients with OAC for 12 months, patients with OAC for 6 months and distal DVT, and
patients with OAC for 6 months and proximal DVT.
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December Supplement 201154S Gremmel et alsP-selectin and D-dimer concentrations after discontinua-
tion of OAC, respectively.15,19,40,41 Recently, patients with
a first VTE and increased D-dimer levels 1 month after
discontinuation of anticoagulant therapy were randomly
assigned either to resume or to stop OAC.42 Thereby, the
resumption of OAC significantly reduced the risk for recur-
rent VTE in these patients.
Patients were included in the study at the time of acute
DVT. Therefore, we cannot provide data on sP-selectin,
D-dimer, and hs-CRP prior to DVT. Previous reports,
however, found an increased risk for a first VTE in patients
with increased levels of D-dimer and hs-CRP, respec-
tively.18,22,23 Another limitation of our study is its relatively
small sample size. Our data are robust, however, because
we followed patients over a period of 1 year, and performed
serial measurements at the time of DVT diagnosis and at
various time points after diagnosis of DVT, including mea-
surements after cessation of oral anticoagulation. More-
over, we compared levels of sP-selectin and hs-CRP to an
age- and gender-matched healthy control population.
Since we only included patients with acute DVT, we cannot
provide data on the effects of OAC on patients receiving
anticoagulant therapy for other indications (eg, atrial fibril-
lation). Additional studies are warranted to investigate sP-
selectin and D-dimer in different patient populations with
anticoagulant therapy.
In conclusion, concentrations of sP-selectin and D-
dimer after acute DVT seem to be strongly influenced by
treatment with vitamin K antagonists. After withdrawal of
oral anticoagulation, they rise again and could therefore
reflect a prothrombotic state, which is susceptible to phar-
macologic therapy. In contrast, the elevated levels of hs-
CRP in acute DVT might mirror the acute phase reaction.
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